Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Pfizer, J&J urge clarity from FDA on future of COVID-19 vaccine trials once a vaccine is available

10/22/2020 | 12:44pm EST

Oct 22 (Reuters) - Pfizer Inc and Johnson & Johnson are seeking input from a U.S. Food and Drug Administration advisory committee on retaining and attracting volunteers for COVID-19 vaccine trials after a vaccine becomes available, if they know they might receive a placebo.

Both U.S. companies are among a handful with pivotal, late-stage COVID-19 vaccine trials underway.

The comments in letters ahead of the meeting of expert advisers on Thursday underscore dilemmas facing leading coronavirus vaccine developers and those whose large trials are just beginning or being planned.

Drugmakers are racing to find vaccines to protect against the coronavirus that has caused more than 1 million deaths globally. Many have begun trials involving tens of thousands of people who receive either an experimental vaccine or a placebo without knowing which.

J&J, in its comments, said a discussion is needed on the potential challenges of maintaining trial enrollment in ongoing large studies, especially after initial vaccines become available.

It is likely several vaccines will be needed to inoculate billions of people around the world.

The company said that once the first vaccines are licensed or authorized, it may lead volunteers to seek available vaccines instead of participating in ongoing trials. Volunteers already enrolled in trials might withdraw, it warned.

Pfizer, which is developing its vaccine with Germany's BioNTech SE, could provide early data from their late-stage vaccine trial later this month. Moderna Inc is likely to have early data on its candidate in November.

The FDA will then consider whether to issue a quick emergency use authorization (EUA), given the desperate need for a vaccine, or seek additional data before making a decision.

J&J is a step behind after its U.S. trial was paused earlier this month due to an illness in a study participant. AstraZeneca's U.S. vaccine trial is also paused due to an illness in its UK trial, but is expected to resume as soon as this week, Reuters reported, citing four sources.

In its guidance on EUAs for vaccines, the FDA said earlier in October that a drugmaker should continue to collect data in any ongoing trials for as long as feasible, even after getting an authorization, and work toward submission of a formal approval application as soon as possible.

Pfizer said it may have an ethical duty to inform at least some study volunteers that they have been given a placebo. It has proposed allowing them to move over to the vaccine arm of the study should its vaccine receive an EUA. (https://bit.ly/3dQqSxP)

J&J said it was evaluating a number of measures aimed at retaining trial volunteers.

"It would be helpful if FDA could share insights at the upcoming (meeting) on potential options they believe can be acceptable," J&J said. (https://bit.ly/37vCKEl)

(Reporting by Ankur Banerjee in Bengaluru, Julie Steenhuysen in Chicago and Michael Erman in New York; editing by Caroline Humer and Bill Berkrot)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.28% 7770 Delayed Quote.2.14%
MODERNA, INC. 16.35% 127.03 Delayed Quote.549.44%
PFIZER INC. 1.92% 37.23 Delayed Quote.0.30%
All news about ASTRAZENECA PLC
12:10pASTRAZENECA : India regulators probe alleged AstraZeneca shot reaction, trial co..
RE
07:42aUK secures two million more doses of Moderna's COVID-19 vaccine
RE
05:55aASTRAZENECA : UK confirms H5N8 bird flu on English turkey farm
RE
11/28Serum Institute CEO sees AstraZeneca's COVID-19 vaccine as "very good" candid..
RE
11/28Serum Institute CEO sees AstraZeneca's COVID-19 vaccine as "very good" candid..
RE
11/28UK regulator set to approve COVID-19 vaccine next week - FT
RE
11/28India's Modi visits key vaccine facilities as COVID-19 cases surge
RE
11/28UK appoints vaccines minister to oversee COVID inoculations
AQ
11/28India's Modi visits key vaccine facilities as COVID-19 case load surges
RE
11/28Oil prices post weekly gain ahead of OPEC+ meeting
RE
More news
Financials (USD)
Sales 2020 26 512 M - -
Net income 2020 2 998 M - -
Net Debt 2020 13 181 M - -
P/E ratio 2020 43,5x
Yield 2020 2,72%
Capitalization 136 B 136 B -
EV / Sales 2020 5,62x
EV / Sales 2021 4,89x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121,49 $
Last Close Price 103,45 $
Spread / Highest target 50,3%
Spread / Average Target 17,4%
Spread / Lowest Target -36,2%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC2.14%135 908
DAIICHI SANKYO COMPANY, LIMITED56.60%72 682
JIANGSU HENGRUI MEDICINE CO., LTD.17.92%69 850
YUNNAN BAIYAO GROUP CO.,LTD7.23%18 673
ORION OYJ-3.10%6 712
SWEDISH ORPHAN BIOVITRUM AB1.42%5 440